Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
GAITHERSBURG, Md., Sept. 08, 2016 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in Washington, D.C. OpGen CEO Evan Jones will lead a presentation titled “Harnessing the power of informatics and genomic analysis to provide complete MDRO solutions” on Thursday, September 8 at 3:05 p.m. ET.
OpGen will also host a roundtable discussion called “Antibiotic resistant bacteria in our Integrated Healthcare Network: are new diagnostic tests needed?” on Friday, September 9 from 1:40 p.m. to 2:20 p.m. ET. The roundtable will feature Bert Lopansri, M.D., Associate Professor of Medicine, University of Utah; Chief of Infectious Diseases, Intermountain Healthcare; and Medical Director, Urban Central Region Microbiology Lab, Division of Infectious Diseases and Epidemiology.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
OpGen Michael Farmer Director, Marketing (240) 813-1284 [email protected] [email protected] Investor Relations LHA Kim Sutton Golodetz (212) 838-3777 [email protected] or Bruce Voss (310) 691-7100 [email protected] OpGen Media MacDougall Biomedical Communications Cammy Duong 781-235-3060 [email protected]
